Last $22.85 USD
Change Today -1.35 / -5.58%
Volume 283.0K
As of 2:51 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $38.50
52 Week Low
05/9/14 - $13.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and database systems for mapping cellular pathways, as well as its computational modeling and simulation platform; LEAP, a proprietary laser-enabled analysis and processing technology; and mAbLogix, a proprietary antibody discovery platform that enables production of B-cell libraries for discovery of antibodies. It has collaborations with ZIOPHARM Oncology, Inc.; Elanco, Inc.; Fibrocell Science, Inc.; Oragenics, Inc.; Synthetic Biologics, Inc.; AquaBounty Technologies, Inc.; AmpliPhi BioSciences Corp.; Genopaver, LLC; and Soligenix, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in West Palm Beach, Florida.

223 Employees
Last Reported Date: 03/31/14
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Founder and Chief Science Officer
Total Annual Compensation: $499.2K
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals S...
Total Annual Compensation: $341.0K
Executive Vice President of Scientific & Publ...
Total Annual Compensation: $485.3K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

Intrexon Names Christopher Basta Vice President of Investor Relations

Intrexon Corporation announced the appointment of Christopher Basta as Vice President of Investor Relations, effective immediately. Mr. Basta will report directly to Chairman and Chief Executive Officer Randal J. Kirk. Mr. Basta brings more than 18 years of financial experience to Intrexon. Most recently, he was a consultant for DSP Group directing its investor relations initiatives.

Intrexon Corporation Presents at World Congress on Industrial Biotechnology, May-12-2014

Intrexon Corporation Presents at World Congress on Industrial Biotechnology, May-12-2014 . Venue: Philadelphia, Pennsylvania, United States.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Intrexon Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net income attributable to Intrexon of $4.1 million, or $0.04 per basic and diluted share compared to net loss attributable to Intrexon of $36.3 million or $7.54 basic and diluted for the quarter ended March 31, 2013. Adjusted EBITDA was $17.6 million, or $0.18 per basic and diluted share compared to adjusted LBITDA of $7.0 million or $0.09 per basic and diluted share for the quarter ended March 31, 2013. Total revenues were $7.9 million compared to $3.9 million for the quarter ended March 31, 2013, an increase of $4.0 million, or 102.2%. Operating loss was $17.872 million against $14.006 million a year ago. Income before tax was $3.555 million against loss before tax of $36.362 million a year ago. Net income attributable to common shareholders was $4.115 million against net loss attributable to common shareholders of $42.716 million a year ago. EBITDA was $6.218 million against LBITDA of $34.429 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $22.85 USD -1.35

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $163.02 USD -4.02
MorphoSys AG €72.25 EUR -0.11
XOMA Corp $3.85 USD -0.085
View Industry Companies

Industry Analysis


Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 84.9x
Price/Book 5.7x
Price/Cash Flow 1,654.0x
TEV/Sales 77.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at